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Abstract
In recent years, there have been signiﬁcant
advances in the clinical management of
patients with wet age-related macular
degeneration (wet AMD)Fa rapidly
progressing and potentially blinding
degenerative eye disease. Wet AMD is
responsible for more than half of registered
severe sight impairment (blindness) in the
United Kingdom, and patients who are being
treated for wet AMD require frequent and
long-term follow-up for treatment to be most
effective. The clinical workload associated
with the frequent follow-up required is
substantial. Furthermore, as more new
patients are diagnosed and the population
continues to age, the patient population will
continue to increase. It is thus vital that
clinical services continue to adapt so that they
can provide a fast and efﬁcient service for
patients with wet AMD. This Action on AMD
document has been developed by eye health-
care professionals and patient representatives,
the Action on AMD group. It is intended to
highlight the urgent and continuing need for
change within wet AMD services. This
document also serves as a guide for eye health-
care professionals, NHS commissioners, and
providers to present possible solutions for
improving NHS retinal and macular services.
Examples of good practice and service
development are considered and can be drawn
upon to help services meet the recommended
quality of care and achieve best possible
outcomes.
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Introduction
Neovascular wet age-related macular
degeneration (AMD) is a serious macular
disorder resulting in progressive loss of central
vision. In the United Kingdom, wet AMD
accounts for more than half of all cases of
registered severe sight impairment (blindness)
and sight impairment.
1,2 There are B26000 new
cases of wet AMD each year in the United
Kingdom.
3 The prevalence of wet AMD is
continuing to increase with the ageing
population.
4 Signiﬁcant vision can be lost in a
short time if wet AMD is not adequately
treated,
5 and this can have a huge impact on
independence and quality of life for patients.
6
Until 3 years ago, the only available licensed and
NICE-approved treatment option for wet AMD
was verteporﬁn photodynamic therapy (vPDT),
which was only suitable for a small proportion of
eyes.
7 Patients with minimally classic and occult
lesions, which account for 55–70% of all patients
with wet AMD, were not eligible for treatment
with vPDT.
8 Signiﬁcant advances have been made
in recent years with the advent of intravitreal anti-
vascular endothelial growth factor (anti-VEGF)
treatment that is effective in patients with wet
AMD of any lesion type.
The National Institute for Health and Clinical
Excellence (NICE)-recommended treatment for
wet AMD is currently ranibizumab (Lucentis
s!),
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9 The Scottish Medicines Consortium (SMC)
approved ranibizumab before NICE and, subsequently,
NHS Quality Improvement Scotland has advised that
NICE recommendations are valid for Scotland as well. The
SMC also approved pegaptanib (Macugen
s), another
licensed anti-VEGF treatment as an alternative, although
this is not widely used. Ranibizumab has proven efﬁcacy in
preventing visual loss in patients with wet AMD and can
also signiﬁcantly improve vision in more than one-third of
patients, with generally good tolerability.
9–11 The
improvement in visual acuity (VA) seen with this treatment
also translates into improved patient-reported beneﬁts in
quality of life (near activities, distance activities, and
activity of daily living tasks).
12–14
The guidance from NICE (in 2008) and the SMC (in
2007) recommending intravitreal ranibizumab treatment
for all wet AMD patients, irrespective of lesion type,
meant that the number of patients potentially suitable for
treatment rose markedly. Furthermore, the number of
clinic visits required for each patient increased because
patients receiving ranibizumab require monthly follow-
up (compared with every 3 months following vPDT).
Many local wet AMD services in the NHS adapted to
meet these increases in demand, and there have also been
substantial improvements in rapid referral and fast-track
processes for new patients.
Despite these initial improvements and service
adaptations, limited or inadequate clinical capacity
continues to threaten optimal care and access to potentially
sight-saving treatment for wet AMD patients. Some NHS
clinics are failing to maintain recommended follow-up
intervals for patients with wet AMD. Delay in follow-up
beyond the recommended interval may cause patients to
unnecessarily lose vision permanently. This is important
because sight impairment and severe sight impairment are
associated with costs in the United Kingdom health-care
system, totalling d22 billion in 2008.
15 These costs include
d2.14 billion direct costs (general ophthalmic services costs:
d484 million, hospital expenditure: d593 million, costs
associated with injurious falls: d25 million) and d4.34
billion indirect costs (including d2.03 billion informal care
costs). The total costs also include d16 billion burden of
disease costs, which put a monetary value on individuals
losing quality of life because of sight loss.
15
Increases in wet AMD patient numbers are expected to
be continuous because of the long-term nature of the
disease, as well as the ageing population. Pressures on
clinical capacity in the hospital eye service (HES) may
also be compounded in the future by new indications for
intravitreal treatments and the availability of future new
treatments for retinal diseases such as diabetic macular
oedema (DMO) and retinal vein occlusion (RVO).
16–18
Slow-release preparations for wet AMD are being
developed, but may not be available for some time.
Furthermore, the United Kingdom has the lowest ratio of
consultant ophthalmologists per 100000 of the general
population in the European Union.
19
It is clear that robust and long-term retinal service
models must be rolled out in order to meet the needs of
local populations both currently and in the future. Action
on AMD strongly advises that every hospital with a
retinal service start this process now, so that there is no
compromise later in the standard of service provision,
duration of follow-up, and quality of intravitreal
treatment administration. Fast-track patient referral
systems from primary care combined with prompt
commencement of therapy in ophthalmology care and
regular monthly follow-up, as per NICE guidance and
Royal College of Ophthalmologists (RCOphth)
guidelines, are vital to the management of patients with
wet AMD. There must be no compromise to patients’
safety, efﬁcacy of the treatment, or patient outcomes.
Key capacity issues
Modelling exercises (using national averages) have
shown that the number of assessment appointments
drives the need for increased capacity rather than the
number of intravitreal injection appointments
(unpublished data provided by Novartis). Thus, patient
follow-up appointments are usually the bottleneck. This
is important as the evidence shows that, with current
licensed and recommended treatment, frequency of
follow-up appointments for wet AMD patients must
continue to be monthly and cannot be reduced without
compromising patient outcomes.
20
It follows that a solution for many providers involves
increasing capacity within follow-up clinics. In some HES
facilities, pressure on optical coherence tomography (OCT)
clinical imaging services is being aggravated by the
increasing use of OCT imaging for other ophthalmic
disorders such as glaucoma, and recent guidance from
NICE requiring optic disc imaging in glaucoma patients.
21
Action on AMD has identiﬁed a number of key capacity
issues that are summarised in Table 1. Although these are
commonly occurring issues, Action on AMD acknowledges
that not all of these issues will apply to every clinic.
Clinical capacity issues largely fall into one of
ﬁve categories, relating to the following: (1) clinic
spaceFshared with other services or limited in
physical size; (2) stafﬁngFshortages in numbers
of key staff and/or inadequacies in skills and training;
(3) equipmentFinsufﬁcient, equipment used is not
the best available, or other clinical pressures for use of
equipment; (4) support and qualityFsuboptimal provision
of patient support or inability to carry out monthly
monitoring of patients; (5) fundingFbusiness case is
either inaccurate, not sufﬁciently long term, not agreed,
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Eyeor not implemented. The consequences of these issues
are serious and threefold:
  Clinics run at maximum capacity with no scope for
further expansion of service. They may even be unable
to cope with the current patient numbers and may not
provide the recommended standard of care.
  Inferior or compromised patient quality of care, which
may be detrimental to patients’ quality of life and
disease outcomes.
  Substantial pressure on staff.
Possible approaches and key considerations: case
studies
Individual wet AMD provider services differ in their
structure, size, and patient population, as well as in the
speciﬁc limitations of the service. Thus, it is highly
unlikely that one single solution will be suitable for every
clinic. Instead, Action on AMD believes that there are a
number of possible solutions. In addition, Action on AMD
believes that it is useful to learn from clinical service
models that work. We have therefore shared some
exemplar case studies here including examples where
novel solutions and models have been used successfully,
to illustrate that current capacity problems are not
insurmountable. These case studies span a range of
useful solutions and can be implemented with or without
further local adaptation. For implementation of change,
the key is to implement a particular model. The speciﬁcs
of the roles of different professional groups will need to
be deﬁned but should not be the primary focus.
Exemplar case study: expanded roles for non-consultant
clinical staff (Gloucestershire)
Gloucestershire provides a one-stop clinic service, with
assessment and treatment clinics running in parallel.
Non-consultant staffFparticularly nurse practitioners
and optometristsFtake key roles, helping to maximise
capacity and maintain monthly follow-up of patients.
Service structure. Initial assessment of new patients is
led by optometrists and nurse practitioners who take the
patient’s history and perform primary examinations
(including Early Treatment Diabetic Retinopathy Study,
ETDRS; visual acuity, VA) and diagnostic imaging
(Figure 1). All data are recorded in an Electronic Medical
Record (EMR; Medisoft
s,M e d i s o f tL i m i t e d ,L e e d s ,U K )
system. If wet AMD is suspected, the diagnosis is ﬁrst
conﬁrmed at specialist clinics using fundus ﬂuorescein
angiography (FFA) before the patient is referred to the wet
A M Dt r e a t m e n tc l i n i c .T h i se n s ures a homogeneous patient
population in the wet AMD clinic and stereotyped clinical
care. An optometrist undertakes refraction at presentation
and annually. OCT technicians work with optometrists to
collect OCT and slit lamp data. Nurse practitioners perform
LogMAR VA analysis and measure best corrected visual
acuity (BCVA). Because all clinical data are recorded
electronically, the retinal consultant is able to make rapid
treatment decisions for new and returning wet AMD patients
using the EMR. If necessary, the consultant ophthalmologist
can also view previous OCT scans on the EMR and examine
the patient themselves. As the nurses and optometrists gain
experience, they are able to make clear ‘observe’ and obvious
‘re-treat’ decisions. If intravitreal treatment is required, a
second retinal specialist administers the injection, assisted
by two nurses who assist with injection preparation.
If, after 18 months from ﬁrst referral, a patient has not
required an intravitreal injection for at least 6 months,
they are moved to an optometrist-led stable AMD clinic
to ease pressure on the assessment clinic.
Clinic capacity. Three assessment/treatment clinics take
place per week, each comprising 40–45 follow-up
assessments, 5–8 planned initial injections, and
approximately 15–25 ‘as required’ injections. Eight to ten
patients are examined per session in the stable clinic, and
frequency depends on patient numbers.
Key requirements. An EMR system is required, as well
as networked OCT instruments. Development of nurse
practitioner and optometrist skills have been necessary,
to be able to perform the necessary examinations and
record data in the EMR. It can also become possible for
nurses to make clear ‘observe’ and ‘re-treat’ decisions.
For the assessment clinic, three nurses perform LogMAR
BCVA and three pairs of OCT technicians and
optometrists carry out OCT and slit lamp examinations.
One medical retinal consultant moves between the three
clinical assessment rooms. Two nurses and one other
retinal doctor are required for the treatment clinic and,
for the stable clinic, one hospital-based optometrist is
required. There is one full-time clinic coordinator, but
secretarial support is reduced as correspondence is
automatically generated by the EMR system.
Learning points
Beneﬁts Challenges
K Conﬁrmation of diagnosis by
FFA prior to admission to wet
AMD clinic ensures a
homogeneous population,
allowing standardised
treatment
K EMRs allow detailed audit of
clinical outcomes and linking
to the hospital patient
information service enables
patient tracking from check-
in to treatment. Waiting times
can also be measured at every
step
K Expanding the roles of
non-consultant clinical staff
maximises capacity and
facilitates monthly follow-up
K A robust business
plan is required
K Accurate monitoring
of data and activity is
required
K Requires substantial
clinic and waiting
room space
* This may
necessitate
moving other
services
K Model beneﬁts from
accurate prediction
of numbers of stable
patients
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EyeExemplar case study: The Mobile Community Eye Care
Project, design and commission of a mobile eye care
clinic for wet AMD (York)
The Mobile Community Eye Care Clinic (MCECC) is a
purpose-built, one-stop mobile clinic, designed to
increase capacity for the management of wet AMD
patients. Its mobility enables it to be used at a number of
different sites during the 4-week cycle of wet AMD care,
abolishing the need for multiple static sites. It functions
in conjunction with the hub site, which remains the
diagnostic centre.
Service structure. Patients diagnosed with wet AMD at
the hub site can be referred to the MCECC for follow-up
and treatment. The MCECC has facilities for measuring
VA, including an optometrist facility for performing
initial, 12-monthly and ‘as needed’ refraction (Figure 2),
as well as retinal imaging facilities (OCT), slit lamp, and
intraocular pressure (IOP). If the consultant decides that
treatment is needed, an initial dosing regime is initiated
(doses are administered at 4-week intervals) in a
dedicated treatment room. Patients at high risk of
needing further treatment are followed up every 4 weeks
and are suited to a one-stop service, with consultant-led
Referral from community optometrist
with suspected wet AMD
RETINAL RAPID ASSESMENT CLINIC
asap within 1 week of referral
History taken, VA, IOP & OCT
Patients may be referred
directly here (e.g. From
General Ophthalmic Clinic)
FFA & Review Clinic
FFA
(VA & IOP if necessary)
suspected wet AMD —
refer to FFA & Review Clinic same day or < 1week
Discharge
(or follow-up as appropriate)
not
wet AMD
Refer for appropriate
follow-up
Discharge
(or follow-up as appropriate)
not
wet AMD
Stable AMD Clinic
Wet AMD Treatment Clinic
Wet AMD Treatment Clinic
Wet AMD Treatment Clinic
wet AMD–
refer to Treatment Clinic within 1week
VA, OCT, slit lamp
VA, LogMAR & 2nd intravitreal injection
VA, LogMAR, refraction, slit lamp BIO,
(OCT if required)
& 1st intravitreal injection (if required)
worse than
1.3 LogMAR/
6/96 Snellen
4 weeks
4 weeks
VA, LogMAR & 3rd intravitreal injection
Wet AMD Treatment Clinic
4 weeks
VA, LogMAR, OCT, slit lamp BIO,
& intravitreal injection (if required)
seen 18/12 with no injection 6/12
regular
follow-up
4 weekly
follow-up
if treatment
indicated
Figure 1 Patient pathway for expanded non-consultant roles (Gloucestershire example). AMD, age-related macular degeneration;
BIO, biomicroscopy; FFA, fundus ﬂuorescein angiogram; IOP, intraocular pressure; OCT, optical coherence tomography; VA, visual
acuity.
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Eyeassessment clinic and treatment at the same visit.
Patients at a low risk of needing further treatment
can either be assessed and treated if necessary at the
MCECC or assessed by community optometrists
and referred to the MCECC for treatment as a
two-step process that may be more convenient for
the patient.
Clinic capacity. The MCECC has capacity for two
optometrists and two OCT instruments. It is estimated to
be able to increase the capacity of an existing ophthalmic
clinic by 40–50 patients per day.
Key requirements. The mobile clinic is assembled on
site from three articulated lorry trailers. A 2.5h assembly
time and overnight/weekend relocation enable seamless
continuity of the service. The MCECC is staffed
by the local hospital staff, or additional staff can be
offered to run the service under overall control and
governance of the local HES. Contracted maintenance
staff are provided (driver, management, and emergency
cover), and thus local units only need to be involved
in clinical management. The unit includes imaging
equipment, core patient database and electronic patient
records (including audit tool), disabled access, a staff
room, and a dedicated intravitreal treatment clean
room.
Learning points
Exemplar case study: nurse-led rapid access clinics and
virtual review clinics (Shefﬁeld)
A rapid access clinic led by a nurse consultant has
been set up in Shefﬁeld. This clinic allows new patients to
be triaged to the appropriate clinic on the basis of initial
assessments, allowing the consultant ophthalmologist’s
time to be utilised more effectively. In addition, nurses
also lead the photographic review clinic for returning
patients, helping to relieve clinical workload of large
numbers of monthly follow-up patients.
Service structure. A two-stop model allows the
workload to be planned and is suitable for the urban
Shefﬁeld area, as most patients only travel short
distances. New referrals are examined at a weekly
nurse-led rapid access clinic, with any overﬂow being
booked into the doctors’ clinic (Figure 3). Patients are
assessed, diagnosed, and triaged by the nurse and
referred appropriately. Information about intravitreal
treatment is given to the patient by the nurse, where
appropriate. For wet AMD patients, images and notes are
discussed in a weekly reporting session (virtual clinic)
involving a multidisciplinary team, during which
treatment decisions are made. If appropriate, patients
are then booked in for intravitreal anti-VEGF treatment
Beneﬁts Challenges
K Additional capacity
to existing services
can be added
quickly
K Needs to be constantly
in use at single or
multiple sites to be
highly cost-effective
K Better patient
experience and
reduced patient
travelling time
K The mobile clinic
comes with an
additional cost per
patient to the tariff
K Quality of care and
face to face contact is
maintained
K Complex to set up
(design, locations,
maintenance)
K Dedicated intravitreal
injection clean room and
equipment
K Leasing on a 4-weekly cycle
enables patients to be seen
every 4 weeks, removing
slippage of follow-up times
and reducing clinical risk
K Expansion of
stafﬁng may
be required
K Provides
supplementary
capacity for main
hub rather than
replacement
K Assessments by
community
optometrists require
negotiation with
commissioners for
funds to follow the
patient, availability of
OCT facilities and an
appropriate IT
infrastructure
Patient check-in
At reception desk
Visual Acuity
Optometrist facility available if refraction is required
(for 1st visit, 12 monthly or as required for borderline
visual acuities for continuation)
and for low vision services
OCT, IOP & slit lamp BIO
Measurements performed
Does
patient require
treatment?
Treatment
YES
Patient returns home
NO
In dedicated treatment area,
IOP, BP and refreshments
(as required)
Followed-up as appropriate
Figure 2 Mobile Community Eye Care Clinic patient
pathway (York example). BIO, biomicroscopy; BP, blood
pressure; IOP, intraocular pressure; OCT, optical coherence
tomography.
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Eyeby the clinic coordinator. Treatment is administered
by a retinal consultant in a dedicated minor
operations theatre. Four-weekly photographic reviews
are carried out in a nurse-led clinic with dedicated
ophthalmic imaging room and a team of ophthalmic
photographers, allowing for multiple patients to be
examined simultaneously. Images are reviewed by the
medical consultants and nurse consultant at the weekly
reporting session, allowing timely and appropriate
management. Where necessary, some patients may
receive photographic review and intravitreal injection on
the same day.
Clinic capacity. Three rapid access and review clinics
are held per week, with a total of 35 patients assessed per
week. There is a weekly capacity of 84 patients on the
intravitreal injection lists and 84–90 patients in the
photographic review clinics. Four reporting sessions are
held per week.
Key requirements. A key requirement of this service is a
senior nurse or nurse consultant who is able to lead the
New referral
Rapid Access Clinic
Nurse Consultant
OCT / Colours (+/- FA / ICG)
IVT information given to
patient
Is
diagnosis wet
AMD?
YES
NO
Follow-up
as appropriate
e.g. BRVO, CSR
NO
Discharge YES Refer to Dr Clinic UNCERTAIN
Virtual Reporting Session
Medical / Nurse Consultants
all notes / images reported on 
Photographic Review Clinic
Appt. in 4 weeks
Dr administration
(new pts. Booked X 3 injections)
Intravitreal injection
Patient referrals from Eye
Casualty Department may
also be sent directly here
Medical Retinal Consultants
Urgent appointment
Is
there available
capacity in the rapid
access
clinic?
YES
Is
diagnosis dry
AMD?
 
Does
patient require IVT 
injection?
  NO YES
Appt. in 4 weeks
Nurse-led clinic
Assess VA / Pt. Perception /
comments / OCT / Colours
NO
Figure 3 Nurse-led and virtual patient pathway (Shefﬁeld example). AMD, age-related macular degeneration; BRVO, branch retinal
vein occlusion; CSR, central serous retinopathy; FA, ﬂuorescein angiography; ICG, indocyanine green angiography; IVT, intravitreal
treatment; OCT, optical coherence tomography; VA, visual acuity.
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imaging, cannulation and administration of contrast
medium, diagnosis of other pathologies, talking to
patients about ﬁndings, triaging, and referring to low
vision assessment services or other appropriate clinic), is
involved in review of retinal images at the reporting
sessions (alongside the medical consultants), can list
patients for treatment and re-treatment, and can
prescribe anti-VEGFs. Ophthalmic staff nurses who can
undertake the photographic review clinics are also
required. Shefﬁeld has four such nurses at present.
Experience from Shefﬁeld is that two AMD clinic
coordinators are required to organise the clinics and
intravitreal treatment lists, liaise directly with patients to
ensure timely treatment, organise patient transport, data
capture, and provide patients with the outcome of their
photographic review.
Learning points
Exemplar case study: utilisation of a peripheral clinic
and mobile screening (Southampton)
A peripheral clinic was originally set up to complement
the Southampton Eye Unit, easing pressure on clinic
space at the main hospital eye unit and resulting in a
more patient-friendly service. Furthermore, a mobile
assessment unit is now being developed, to provide an
even more convenient service for patients and reduce
transport costs.
Service structure. Initially, a peripheral clinic was set up
in a large health centre, with facilities for OCT imaging
and intravitreal injections. Patients were diagnosed and
had their ﬁrst injection at the main hospital eye unit
(Figure 4). Subsequently, they were booked for injections
or follow-up at the peripheral health centre, providing a
one-stop service. The service at Southampton no longer
uses the peripheral clinic at the health centre. Instead,
follow-up patients from three peripheral hospitals will
attend a mobile assessment unit (stationed at the local
hospital) for assessment of VA and OCT imaging. A
medical retinal consultant at the main hospital eye unit
will review the images, and, if necessary, patients will be
booked for treatment at the peripheral hospital.
Clinic capacity. Southampton Eye Unit currently
undertakes B20 OCT scans per instrument per session
(and has two OCT instruments), with 600–700 patients
seen per month and around 300 intravitreal injections
administered per month. The OCT scan van is expected
to have capacity to screen 10 patients per session, and
B30 OCT images are expected to be reviewed per virtual
session by the ophthalmologist.
Key requirements. The peripheral clinic required an OCT
instrument, operated by a clinical photographer and an
ophthalmologist to assess the patients. A second
ophthalmologist performed the intravitreal injection,
assisted by a nurse. For mobile assessment, in addition to
the van itself, equipment and staff are required for OCT
fundus imaging and VA assessment. There is a need for
high-quality IT to enable large ﬁle-size images to be sent
from the van to the main unit for assessment by the
retinal specialist.
Learning points
Beneﬁts Challenges
K Rapid access clinic provides
extra capacity for patients
who need to be seen
promptly and fast access to
treatment
K Requires additional
retinal cameras and
OCT instruments,
photographic staff and
training for them
K Nurse-led photographic
review clinics can help
to more effectively manage
the large numbers of
monthly follow-up
patients
K Reporting session
triages patients to the
appropriate clinic based
on clinical ﬁndings,
allowing for more
efﬁcient use of time and
equipment
K Maximises individual
professionals’
potential
K Dedicated equipment
and space to
accommodate the
optometrists
K Requires a dedicated
minor operations
theatre for intravitreal
treatment
K Covering staff leave
can be challenging,
with speciﬁc
challenges on covering
review clinics and the
reporting session
Beneﬁts Challenges
Peripheral clinic
K Helped overcome lack of
space at the main hospital
eye unit
K Easier parking/access for
patients
K No facility to run
large clinics
K OCT instrument was
only in use 2 days
per week
K More patient-friendly
environment
K A large number of
personnel were
required to treat a
small number of
patients
Mobile screening van
K Reduces patient
travel
K Initial investment
required
K Negates the cost of
purchasing OCT
equipment for multiple
peripheral units
K Large ﬁle sizes can
affect network
integration and NHS
network speeds
K Virtual clinic reduces the
number of medical staff
required to assess a
patient at each visit
K Current OCT
instruments are
built to work as a
stationary unit
K Space constraints are
overcome
K Efﬁcient booking
service required
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approach to patient management and satellite
macular clinics in the community (Sunderland
Eye Inﬁrmary)
Sunderland Eye Inﬁrmary (SEI) uses a teamwork
approach that extends the role of hospital optometrist,
nursing, and health-care staff as ‘macular specialist staff’
for provision of a service in an area with higher than
average incidence of wet AMD.
Service structure. All new patient referral requests are
directed by rapid access referral to a named ‘on take’
medical retinal consultant who allocates the patient
either to triage or directly to the AMD specialist clinic
(Figures 5a and b). Triage clinics are undertaken by
hospital optometrists to identify any false-positive wet
Referral with suspected wet AMD
Main Hospital Eye Unit
Diagnosis and 1st injection
Is patient
suitable for follow-up
AMD scan van?
Peripheral Hospital
2nd & 3rd injections (4 week intervals)
LOADING
PHASE
Main Hospital Eye Unit
Review
Main Hospital Eye Unit
NO
(appt. in 4
weeks)
AMD Scan Van
YES
(appt. in 4
weeks)
Main Hospital Eye Unit
Peripheral Hospital
VA, OCT, fundus imaging
Does
patient require IVT
injection?
NO
(appt. in 4 
weeks)
YES
IVT injection
appt. in
4 weeks
Image review (virtual clinic)
VA, OCT, fundus imaging & injection if
required (review at 4 week intervals)
Figure 4 Hub and mobile OCT spoke model (Southampton example). AMD, age-related macular degeneration; IVT, intravitreal
treatment; OCT, optical coherence tomography; VA, visual acuity.
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EyeAMD referrals and redirect patients appropriately. All
patients in whom wet AMD is suspected are reviewed
by a medical retinal consultant, and those requiring
intravitreal treatment have the choice of immediate
(one-stop) treatment or joining a dedicated intravitreal
injection list (two-stop). An Eye Clinic Liaison Ofﬁcer
(ECLO) undertakes a session simultaneous to the
specialist clinic so that patients requiring support can
undergo disability assessment and visual rehabilitation
during the same visit. If a patient has not required
treatment for 6 months, they are followed-up in a
nurse-led review clinic. When patients remain stable
after 24 months from start of treatment, they are seen in
an optometrist-led OCT clinic. ‘Stable’ patients can be
seen at satellite clinics closer to their home, and a mobile
OCT scanner travels to the satellite clinics.
‘On-take’ Medical Retina Consultant
Prioritisation of clinic requests, arrange investigations &
book AMD triage or specialist AMD clinic as required
Referral with suspected wet AMD from community optometrists
(via fax of secure e-referral including OCT images where applicable),
Hospital A&E, General and Outreach clinics
(using ‘blue-slip system’ indicating need for immediate action)
Does
patient prefer
injection
today?
Is
diagnosis of
suspected wet AMD
confirmed?
Does
patient require
direct referral to
specialist AMD
clinic?
Dedicated Injection list
Optometrist run
wet AMD triage clinic
MR Consultant AMD Specialist Clinic Dedicated Injection List
MR Consultant AMD Specialist Clinic
Discharge
or re-direct as appropriate
When vision is stable refer to
‘Stable wet AMD Pathway’
(6 months no VA drop + no retreatment for 6 months or,
>24 months since onset of anti-VEGF treatment with no
VA drop & no injection for last 3 visits)
VA, complete ophthalmic examination
including (if required) FFA,
indocyanine green angiography & OCT
Review patient
1st IVT injection
(one stop service)
2nd & 3rd IVT injections
(4 week intervals)
1st IVT injection
(two stop service, within 1-2 weeks)
NO
YES
YES
NO
Is
diagnosis of
wet AMD
confirmed?
YES
NO
NO YES
MR Consultant AMD Specialist Clinic
Monthly review and ‘one stop’ same day,
or ‘two stop’ (within 1 - 2 weeks)
& injection if required
a
Figure 5 (a) Hub and satellite clinic spoke (Sunderland example). The pathway for newly diagnosed patients and patients with
‘active’ wet AMD. AMD, age-related macular degeneration; FFA, fundus ﬂuorescein angiography; IVT, intravitreal treatment;
MR, medical retinal; OCT, optical coherence tomography; VA, visual acuity; VEGF, vascular endothelial growth factor.
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EyeClinic capacity. In all, 15–20 patients are examined at
each of 2 weekly triage clinics. The AMD specialist
clinics are run six times a week each with capacity
for 8 new patients and 24 follow-up patients, and
17 injection slots. In addition, ﬁve dedicated injection
lists per week increase throughput with 15–20 injections
per session. Each week there are up to three nurse-led
AMD review clinics with 15 patients each and two
optometrist-led OCT review clinics with 30–35
patients each.
Key requirements. Good teamwork is vital to provide
patients with the best health care, and the SEI
Macular Unit staff are ﬂexible in their roles, to ensure
efﬁcient and effective delivery of the treatment.
The staff comprises three medical retinal consultants, two
general ophthalmologists, three optometrists, four
macular specialist nurses, two health-care assistants,
an ECLO, two medical photographers, a macular
secretary/AMD coordinator, and three reception staff.
A dedicated macular unit consisting of a nursing
assessment area, imaging suite, preparation rooms,
and injection suite has been established for the macular
patients.
Learning points
Patient referred from AMD service after 6 months
with no VA drop + no retreatment for 6 months
Patient referred from AMD service >24 months
since onset of anti-VEGF treatment and with no
VA drop and no injections for last 3 visits
Nurse-led wet AMD Review Clinic
LogMAR VA, fundus imaging, colour
fundus / OCT scans, history taking and
clinical examination
Optometrist-led OCT Clinic
Staff nurse or health-care assistant
conduct VA assessment questionnaire
Virtual review of notes and images
by Ophthalmologist
Does
patient require
referral to specialist
AMD
clinic?
Has
patient answered
yes to any questions, or
has a >5 letter drop
in VA
Optometrist-led OCT Clinic
YES
Patient notes reviewed and imaging
reported upon by optometrist
Does 
patient require 
referral to specialist 
AMD 
clinic?
Refer to MR Consultant
AMD Specialist Clinic
YES
YES
NO
NO
NO
b
Figure 5 (b) Hub and satellite clinic spoke (Sunderland example). The pathway for patients classiﬁed as having ‘stable’ wet AMD.
AMD, age-related macular degeneration; MR, medical retinal; OCT, optical coherence tomography; VA, visual acuity; VEGF,
vascular endothelial growth factor.
Beneﬁts Challenges
K Implementation of AMD
triage clinics, nurse-led
review clinics and
optometrist-led OCT clinics
have helped maximise
capacity
K Need to identify, train
and retain appropriate
staff to undertake FFA
and OCT
K Covering staff leave
has been a challenge
K Specialist clinics have
enabled consultants to focus
on complex macular
pathology and high-risk
patients
K Expansion of service
requires expansion of
the clinical area to
maintain increase in
throughput
K Dedicated Macular
Unit and satellite Macular
Clinics in the community
have increased capacity
as well as convenience
for patients
K An appropriate
business case is
required for addition
of satellite macular
clinics
K A mobile OCT scanner
is required
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EyeExemplar case study: e-referral link between community
optometrists and hospital eye clinics (Fife)
In the autumn of 2010, the Scottish Government
announced a d6.6 million investment in a new ITscheme
linking community optometrists and eye clinics within
hospitals across all of Scotland.
22 The link was based on a
successful pilot scheme in NHS Fife and allows
optometrists to send clinical images of patients with
potentially serious eye problems (such as wet AMD)
directly to ophthalmologists, enabling them to decide on
the same day whether the person needs a hospital
ophthalmology appointment. Future development of this
service is expected to reduce the time between patients
visiting the optometrist and receiving an appointment
from the HES and lead to fewer unnecessary hospital
attendances.
Service structure. In the previously published pilot
study,
23 patients visiting one of three optometry practices
with existing non-mydriatic cameras were charged a
small fee for fundus photography, and the images were
forwarded by email to the HES using NHSmail
(www.nhs.net), accompanied by the electronically
redesigned referral form (Figure 6). Each referral was
assessed by a consultant ophthalmologist whose
telemedicine assessment was based solely on the
information and image provided in the referral. The
decision for requiring or not requiring an appointment
within the HES was communicated to the optometrist by
email, and to the patient and GP by letter.
Clinic capacity. In an 18-month trial, 346 patients
were examined. Of these, 128 patients (37%) were found
not to require an HES appointment, considerably easing
the burden on the hospital eye unit. The potential cost
savings of such a scheme are estimated to run into
several hundred thousands of pounds per annum for
individual hospital trusts.
23
Key requirements. Suitable quality retinal imaging
cameras for community optometrists are required. High-
quality IT equipment is also required, as well as special
approval to send large ﬁles containing conﬁdential
clinical information via NHSmail. An appropriately
designed e-referral form is necessary to ensure that all
relevant information is captured in primary optometric
care for accurate decision-making by a remote
secondary-care specialist.
Learning points
Exemplar case study: telemedicine pilot project
with OCT image transfer from community
optometry to ophthalmologist; teleophthalmology
(Salford/Bolton)
In the ﬁrst phase of a pilot project, a community
optometry practice in Salford forwarded consecutive e-
referrals with attached OCT images of retinal patients to
a consultant ophthalmologist based at Royal Bolton
Hospital NHS Foundation Trust. These cases received
rapid referral telemedicine advice and triage or
teleophthalmology.
Service structure. In a pilot study, 43 retinal
patients were assessed during the period June 2010–June
2011. The OCT images of patients’ retinae were captured
and stored locally by the optometrist and then forwarded
Optometrist appointment Optometrist appointment
Flowcharts of old and new referral pathways
OLD (2 - 32 weeks) NEW (1 - 6 weeks)
Awaiting further information / case
notes / transfer to another consultant
Consultant referral file
General hospital medical records
GP’s letter to hospital
Letter to GP
HES appointment
HES appointment or discharge
Consultant review of referral and images
Electronic referral to HES with images
and concomitant information to GP
Figure 6 Telemedicine with community imaging (new vs
old Fife patient pathways). Adapted from Cameron et al. with
permission from the Nature Publishing Group.
23 GP, general
practitioner; HES, hospital eye service.
Beneﬁts Challenges
K Reduces waiting times from
optometrist visit to HES
appointment
K One-stop service
(the right patients are
sent to the right clinic)
K Reduces the number of
unnecessary HES
appointments and fewer
non-macular patients
are seen
K Improved productivity of
NHS resource
* Frees up space in HES
* Potential for cost
savings
K Reduces ‘did not attend’
rates
K Greater patient satisfaction
K Good cooperation and
communication of
HES with GPs and
optometrists is
fundamental to
success of the scheme
(including training for
optometrists)
K Some risk of clinical
oversight may be
associated with
dealing with purely
electronic images and
information
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Eyeusing NHSmail (www.nhs.net) as JPEG ﬁles to the
hospital consultant ophthalmologist (Figure 7). Patients
were charged a small fee for the enhanced imaging. In
the pilot project, the consultant ophthalmologist typically
responded within 24h by remote telemedicine working.
The next phase of the pilot study aims to secure funding
to expand the service to wider eye conditions and make
OCTimaging available to potential participants who may
be unable to pay for community optometrist OCT
imaging.
Key requirements. OCT imaging in primary care
requires equipment, as well as skill in taking and
transmitting appropriate images by the community
optometrist. In addition, the secure email transfer and
centralised data storage systems between different
health-care providers need to be compatible. For roll-out
of this model, relevant primary and secondary, private
and NHS health-care practitioners require access to
NHSmail or N3 connection to enable secure patient
data transfer. A dedicated NHSmail inbox for receipt of
all electronic referrals at Trusts may be of beneﬁt, but
would need to be supported by appropriate resourcing,
to provide continuous management of electronic
referrals. For further details on this exemplar case study,
see Kelly et al.
24
Learning points
Service innovation, summary of approaches
Possible approaches to the various key capacity issues
are summarised in Table 2. Overall, the general
considerations for each of these potential solutions
include costs, staff retention and morale, staff training
and competency assessment, availability (of space, staff,
or equipment), staff leave of absence, management of
complications (eg, safety), and patient acceptance. Other
challenges and considerations that are speciﬁc to each
Community Optometrist
Patient self-referring to
Community Optometrist
Examination including OCT
Community Optometrist
e-referral includes patient history & images
made to Ophthalmology via secure e-mail
Ophthalmologist with
medical retina expertise
Ophthalmology
Review and respond to e-referral
Provide Urgent and Routine clinical review
Does
condition require
ophthalmology
visit?
YES
65%
Appropriate advice
e.g. Further monitoring by Optometrist
NO
35%
Figure 7 Community OCT telemedicine (example from Salford/
Bolton). OCT, optical coherence tomography. Reprinted from
Kelly et al.
24 Copyright 2011, with permission from Dove Medical
Press Ltd.
Beneﬁts Challenges
K Enables rapid referral
telemedicine advice and
triage or teleophthalmology
K Reduces waiting times from
optometrist visit to HES
appointment
K Reduces the number of
unnecessary HES
appointments and fewer
non-macular patients seen
K Improves productivity of
NHS resource
* Frees up space in HES
* Potential for cost savings
K Ensuring that
participating
individuals/
organisations have
appropriate OCT
scanning and viewing
equipment and
adequate training
K Self-pay cost of OCT
scanning in primary
optometric care may
prohibit some patients
in the community
from experiencing
these associated
beneﬁts: NHS funding
for OCT imaging in
primary care and
development of an
NHS tariff for OCT
e-consultation would
be beneﬁcial
K Consistent selection
of the most clinically
appropriate retinal
images by the
optometrist and
consistent provision
of clinical assessment
information to support
the images is
important
* May beneﬁt from
agreement of a
protocol/criteria
for selection of
images and
development of a
bespoke electronic
form, based on the
GOS 18 form
K The size of OCT
images rapidly ﬁlled
NHS email in-boxes.
Full video ﬁle
transmission may
be problematic
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Eyepossible approach are also described in Table 2 and are
drawn from the case studies and expert experience.
Whatever the speciﬁc problem areas that need to be
addressed, effective stakeholder engagement must
inform the approach chosen, including engagement with
patients and patient organisations.
Conclusions and summary
Wet AMD services in many parts of the UK NHS are
under pressure and often running to maximum capacity.
It is vital that services continue to adapt locally to meet
current and future demands, so that they may continue
to provide the best care possible for patients with wet
AMD. There is evidence from patient safety reports from
the NHS and in a survey undertaken by RCOphth that
capacity has been problematic, at times, in the HESs
in the United Kingdom.
25,26 Failure to maintain the
recommended follow-up interval can cause patients to
unnecessarily lose vision permanently, with a consequent
burden on health and social care.
Action on AMD aims to assist eye health-care
professionals and NHS commissioners and providers rise
to the challenge of increasing wet AMD rates and
provide access to optimum care for these NHS patients.
Action on AMD strongly advises that every hospital with
a medical retinal clinic evaluate their wet AMD service
and, wherever necessary, implement modiﬁcations to
ensure that the best possible quality of care is currently
provided, and continues to be provided into the future.
We are aware of pockets of good practice and service
development.
In accordance with the government’s pledge to
support the NHS in providing high-quality and patient-
centred care, the Quality, Innovation, Productivity and
Prevention (QIPP) programme aims to ensure that all
money spent in the NHS is used to bring the most beneﬁt
and quality of care to patients. The Quality Standards
Group of RCOphth has produced a self-assessment tool
for a number of clinical services, including wet AMD.
This tool indicates whether a department is currently
providing an acceptable standard of patient care and can
be used as a quality improvement tool to show where the
service is under stress. Action on AMD supports such an
approach that could be applied to pinpoint which of the
potential solutions presented here would best improve
the quality of patient care in any particular clinic.
Importantly, we have presented here a number of
potential solutions that experience has shown to improve
quality, effectiveness, and productivity, and thus increase
capacity. The examples provided can be implemented in
whole, in part, or in principle, at a local level, and our
key recommendations are summarised in Table 3. For
implementation of change, the broader principle of
adopting a particular model is more important than the
speciﬁcs of which professional group to use. In our
opinion, services for wet AMD patients require clinical
leadership, and, in our opinion, ophthalmologists with
expertise in the management of wet AMD must be
supported by appropriately trained staff, equipment, and
clinical space. Although investment may be necessary to
modify existing services, this can be outweighed by the
provision of better quality care that meets the needs of
patients, increased productivity by maximising the use of
experienced clinicians, and additional revenue to be
invested in the HESs. Importantly, we would also expect
cost reductions in the long term in sight support services
(both health and social care) as more patients retain
vision with better clinical outcomes.
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Table 3 Action on AMD key recommendations
Key recommendations Comments and considerations
1. Appropriate funding and resources must be made
available now that treatment is possible
Wet AMD is a serious and rapidly progressing degenerative eye disease that
can cause blindness if inadequately treated and managed
2. There should be no compromise in the standard of
service provision, or quality or frequency of intravitreal
treatment administration
Fast track referral systems, prompt commencement of intravitreal therapy
and regular monthly follow-up as per NICE guidance and RCOphth
guidelines are vital components of wet AMD patient management
3. Continued evaluation and adaptation/redesign of local
wet AMD NHS service is required
To increase capacity to meet current and future demands. Action must be
taken now in order to ensure services that provide the quality of care that
has been set out by NICE and RCOphth for all patients with wet AMD.
4. Recruitment Recruitment of additional consultant staff, or middle-grade (staff and
associate specialist grade) medical retinal staff to provide assistance for
consultant medical retinal specialists has been identiﬁed as a key element of
any approach to tackle existing capacity problems Optometrists and senior
nurses can be trained to perform assessments.
5. Prioritisation/stratiﬁcation of patients In line with local and regional service designs. Matching the service model
to the stage of the patient journey can be helpful (eg, one-stop model for
patients likely to require treatment and two-stop model for patients for
whom treatment is considered unlikely to be necessary)
6. Virtual clinics To free up capacity issues within the hospital service. Ophthalmology
medical staff may not need to examine every patient, as long as they are still
involved in the decision-making process at vital points in the patient
pathway. Face-to-face patient contact can be undertaken by suitably trained
and supervised nursing and optometry staff. Consideration can also be
given to enhance roles for other staff such as optometrists, orthoptists, and
medical imaging staff.
7. Use of other community spaces such as mobile units,
polyclinics or GP clinics
To relieve problems of inadequate hospital space and to bring care closer to
home
8. Multi-disciplinary clinicsFstaff training and
development, ﬂexible role, and appropriate use of staff
To best suit the individual’s skill set. Consideration should be given to
extending the role of nursing and other health-care professionals
9. Use of community optometrists for monitoring ‘stable’
patients (patients at low risk of requiring treatment)
Requires appropriately connected OCT instruments in the community
setting in addition to OCT instruments and/or viewing software in the
Ophthalmology Departmental setting. Also requires appropriate training of
community optometrists in OCT imaging and NHS Information
Governance
10. Electronic referrals from community optometrists May be worth investment, in order to make triaging more timely, efﬁcient
and better quality. Pilot projects using, eg, retinal photography image
transfer in Scotland have been of merit. Patients have often had, however, to
self-fund such imaging in optometric care
11. Electronic medical records To improve auditing capabilities, reduce administration time, and enable
easier assessment of patient records and prioritisation of patients
12. Employment of an Eye Clinic Liaison Ofﬁcer To guarantee a holistic service that takes account of the emotional support
needs of patients and helps secure a smooth transition from health to social
care and other support services as required
Action on AMD
W Amoaku et al
S18
Eyewho provided medical writing support on behalf of
Novartis Pharmaceuticals.
References
1 Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How
big is the burden of visual loss caused by age related
macular degeneration in the United Kingdon? BJ
Ophthalmol 2003; 87: 312–317.
2 Bunce C, Wormald R. Causes of blind certiﬁcations in England
and Wales: April 1999-March 2000. Eye 2008; 22: 905–911.
3 NICE Technology Appraisal Guidance TA155. Ranibizumab
and pegaptanib for the treatment of age-related macular
degeneration. 2008. Accessed at http://www.nice.org.uk/
nicemedia/pdf/TA155guidance.pdf.
4 Congdon N, O’Colmain B, Klaver CCW, Klein R, Munoz B,
Friedman DS et al. Causes and prevalence of visual
impairment among adults in the United States. Arch
Ophthalmol 2004; 122: 477–485.
5 Bressler NM, Arnold J, Barbazetto I, Birngruber R,
Blumenkranz MS, Bressler SB et al. Photodynamic therapy
of subfoveal choroidal neovascularization in age-related
macular degeneration with verteporﬁn. Arch Ophthalmol
2001; 119: 198–207.
6 Mitchell J, Bradley C. Quality of life in age-related macular
degeneration: a review of the literature. Health Qual Life
Outcomes 2006; 4: 97–117.
7 NICE Technology Appraisal Guidance TA68. Photodynamic
therapy for age-related macular degeneration. 2003.
Accessed at http://www.nice.org.uk/nicemedia/live/
11512/32728/32728.pdf.
8 Royal College of Ophthalmologists. Commissioning
contemporary AMD services: a guide for commissioners
and clinicians. 2007. Accessed at http://www.rcophth.
ac.uk/core/core_picker/download. asp?id¼181&ﬁletitle¼
Commissioningþ ContemporaryþAMDþServices.
9 Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T.
Ranibizumab versus verteporﬁn photodynamic therapy for
neovascular age-related macular degeneration: two-year results
of the ANCHOR study. Ophthalmology 2009; 116: 1, 57–65e5.
10 Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK,
Chung CY et al. Ranibizumab for neovascular age-related
macular degeneration. N Engl J Med 2006; 355: 1419–1431.
11 Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS,
Kim RY et al. Ranibizumab versus verteporﬁn for
neovascular age-related macular degeneration. N Engl J Med
2006; 355: 1432–1444.
12 Bressler NM, Chang TS, Suner IJ, Fine JT, Dolan CM, Ward J
et al. Vision-related function after ranibizumab treatment by
better- or worse-seeing eye. Ophthalmol 2010; 117: 747–756.
13 Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J.
Improved vision-related function after ranibizumab vs
photodynamic therapy. Arch Ophthalmol 2009; 127(1): 13–21.
14 Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert
TR. Improved vision-related function after ranibizumab
treatment of neovascular age-related macular degeneration.
Arch Ophthalmol 2007; 125(11): 1460–1469.
15 RNIB. Future Sight Loss UK (1). The economic impact of
partial sight and blindness in the UK adult population.
2009. Accessed at http://www.rnib.org.uk/aboutus/
Research/reports/2009andearlier/FSUK_Report.pdf.
16 The Diabetic Retinopathy Clinical Research Network, Elman
MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR
et al. Randomized trial evaluating ranibizumab plus prompt or
deferred laser or triamcinolone plus prompt laser for diabetic
macular edema. Ophthalmology 2010; 117(6): 1064–1077.
17 Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle
AC et al. Ranibizumab for macular edema following branch
retinal vein occlusion. Ophthalmology 2010; 117(6): 1102–1112.e1.
18 Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj
N et al. Ranibizumab for macular edema following central
retinal vein occlusion. Ophthalmology 2010; 117(6): 1124–1133.
19 Ocular Surgery News Europe Edition. Growing demand for
eye care services may highlight shortage of
ophthalmologists in Europe. 2010. Accessed at http://
www.osnsupersite.com/view.aspx?rid¼65866.
20 Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S,
Feuer W et al. A variable-dosing regimen with intravitreal
ranibizumab for neovascular age-related macular
degeneration: year 2 of the PrONTO study. Am J Ophthalmol
2009; 148(10): 43–58.
21 NICE Clinical Guidelines CG85. Glaucoma. 2009. Accessed
at http://www.nice.org.uk/nicemedia/live/12145/43887/
43887.pdf.
22 The Scottish Government. Roll-out of IT services for
optometry. News release. 2010. Accessed at http://
www.scotland.gov.uk/News/Releases/2010/09/27113039.
23 Cameron JR, Ahmed S, Curry P, Forrest G, Sanders R.
Impact of direct electronic optometric referral with ocular
imaging to a hospital eye service. Eye 2009; 23: 1134–1140.
24 Kelly SP, Wallwork I, Haider D, Qureshi K. Teleophthal-
mology with optical coherence tomography imaging in
community optometry. Evaluation of a quality improvement
for macular patients. Clin Ophthal 2011; 5: 1673–1678.
25 Kelly SP, Barua A. A review of safety incidents in England
and Wales for vascular endothelial growth factor inhibitor
medications. Eye 2011; 25: 710–716.
26 Royal College of Ophthalmologists. AMD Services Survey.
Royal College of Ophthalmologists: London, 2009. Accessed
at http://www.rcophth.ac.uk/page.asp?section¼295&
sectionTitle¼AMDþServicesþSurvey.
This work is licensed under the Creative
Commons Attribution-NonCommercial-No
Derivative Works 3.0 Unported License. To view a copy
of this license, visit http://creativecommons.org/licenses/
by-nc-nd/3.0/
Appendix
Action on AMD members
Mr Winfried Amoaku (Chair), Associate Professor and
Honorary Consultant Ophthalmologist, Nottingham;
Dr Susan Blakeney, Optometrist and Optometric Advisor,
Kent; Mrs Mary Freeman, Nurse Consultant, Royal
Hallamshire Hospital; Mr Richard Gale, Consultant
Ophthalmologist, York Teaching Hospital; Mr Rob
Johnston, Consultant Ophthalmologist, Cheltenham
General Hospital; Mr Simon P Kelly, Consultant
Ophthalmologist, Royal Bolton Hospital; Ms Barbara
Action on AMD
W Amoaku et al
S19
EyeMcLaughlan, Policy and Campaigns ManagerFEye
Health and Social Care, Royal National Institute of Blind
People; Mr Debendra Sahu, Consultant Ophthalmologist,
Southampton General Hospital; Mrs Deepali Varma,
Consultant Ophthalmologist, Sunderland Eye Inﬁrmary.
Some of the Action on AMD members are also members
of eye health organisations and charities. However,
opinions expressed within this document are those of the
individuals and do not represent the opinions of any
organisations.
Lucentis
s! (ranibizumab) ABBREVIATED UK
PRESCRIBING INFORMATION
Please refer to the SmPC before prescribing Lucentis
10mg/ml solution for injection.
Presentation: A glass single-use vial containing 0.23ml
solution containing 2.3mg of ranibizumab (10mg/ml).
Indications: The treatment in adults of neovascular
(wet) age-related macular degeneration (AMD), the
treatment of visual impairment due to diabetic macular
oedema (DMO), or the treatment of visual impairment
due to macular oedema secondary
to retinal vein occlusion (branch RVO or central RVO).
Administration and dosage: Single-use vial for
intravitreal use only. Lucentis must be administered by
a qualiﬁed ophthalmologist experienced in intravitreal
injections under aseptic conditions. The recommended
dose is 0.5mg (0.05ml).
For treatment of wet AMD: Treatment is given
monthly and continued until maximum visual acuity is
achieved; ie, the patient’s visual acuity is stable for three
consecutive monthly assessments performed while on
ranibizumab. Thereafter, patients should be monitored
monthly for visual acuity.
Treatment is resumed when monitoring indicates loss
of visual acuity due to wet AMD. Monthly injections
should then be administered until stable visual acuity is
reached again for three consecutive monthly assessments
(implying a minimum of two injections). The interval
between two doses should not be shorter than 1 month.
For treatment of visual impairment due to either
DMO or macular oedema secondary to RVO: Treatment
is given monthly and continued until maximum visual
acuity is achieved; ie, the patient’s visual acuity is stable
for 3 consecutive monthly assessments performed while
on ranibizumab treatment. If there is no improvement in
visual acuity over the course of the ﬁrst three injections,
continued treatment is not recommended. Thereafter,
patients should be monitored monthly for visual acuity.
Treatment is resumed when monitoring indicates loss of
visual acuity due to DMO or macular oedema secondary
to RVO. Monthly injections should then be administered
until stable visual acuity is reached again for three
consecutive monthly assessments (implying a minimum
of two injections). The interval between two doses should
not be shorter than 1 month.
Lucentis and laser photocoagulation in DMO and in
macular oedema secondary to BRVO: When given on
the same day, Lucentis should be administered at least
30minutes after laser photocoagulation. Lucentis can be
administered in patients who have received previous
laser photocoagulation.
Before treatment, evaluate the patient’s medical
history for hypersensitivity. The patient should also
be instructed to self-administer antimicrobial drops,
4 times daily for 3 days before and following each
injection.
Children and adolescents: Not recommended for use
in children and adolescents because of a lack of data.
Elderly: No dose adjustment is required in the elderly.
There is limited experience in patients older than 75
years with DMO.
Hepatic and renal impairment: Dose adjustment is not
needed in these populations.
Contraindications: Hypersensitivity to the active
substance or excipients. Patients with active or suspected
ocular or periocular infections. Patients with active
severe intraocular inﬂammation.
Special warnings and precautions for use: Lucentis
is for intravitreal injection only. Intravitreal injections
have been associated with endophthalmitis, intraocular
inﬂammation, rhegmatogenous retinal detachment,
retinal tear, and iatrogenic traumatic cataract. Monitor
during week following injection for infections. Patients
should be instructed to report symptoms suggestive
of any of the above without delay. Transient increases
in intraocular pressure (IOP) within 1h of injection
and sustained IOP increases have been identiﬁed.
Both IOP and perfusion of the optic nerve head should
be monitored and managed appropriately. Concurrent
use in both eyes has not been studied and could lead
to an increased systemic exposure. There is a potential
for immunogenicity with Lucentis, which may be greater
in subjects with DMO. Patients should report an increase
in severity of intraocular inﬂammation. Lucentis should
not be administered concurrently with other anti-VEGF
agents (systemic or ocular). Withhold dose and
do not resume treatment earlier than the next scheduled
treatment in the event of the following: a decrease in best
corrected visual acuity (BCVA) of X30 letters compared
with the last assessment of visual acuity; an intraocular
pressure of X30mmHg; a retinal break; a subretinal
haemorrhage involving the centre of the fovea, or if the
size of the haemorrhage is X50% of the total lesion area;
performed or planned intraocular surgery within the
previous or next 28 days. Risk factors associated with the
development of a retinal pigment epithelial (RPE) tear
after anti-VEGF therapy for wet AMD include a large
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When initiating Lucentis therapy, caution should be used
in patients with these risk factors for RPE tears.
Discontinue treatment in cases of rhegmatogenous
retinal detachment or stage 3 or 4 macular holes.
There is only limited experience in the treatment of
subjects with DMO due to type I diabetes. Lucentis has
not been studied in patients who have previously
received intravitreal injections, in patients with active
systemic infections, proliferative diabetic retinopathy, or
in patients with concurrent eye conditions such as retinal
detachment or macular hole. There is also no experience
of treatment with Lucentis in diabetic patients with an
HbA1c over 12% and uncontrolled hypertension. There
are limited data on safety in the treatment of DMO and
macular oedema due to RVO patients with prior history
of stroke or transient ischaemic attacks. Since there
is a potential risk of arterial thromboembolic events
following intravitreal use of vascular endothelial growth
factor (VEGF) inhibitors, caution should be exercised
when treating such patients. There is limited experience
with treatment of patients with prior episodes of RVO
and of patients with ischaemic BRVO and CRVO.
Treatment is not recommended in RVO patients
presenting with clinical signs of irreversible ischaemic
visual function loss.
Interactions: No formal interaction studies have been
performed. In wet AMD, adjunctive use of verteporﬁn
photodynamic therapy (PDT) and Lucentis in an open
study showed an incidence of intraocular inﬂammation
following initial combination treatment of 6.3% (2 of 32
patients). In DMO and BRVO, adjunctive use of laser
therapy and Lucentis was not associated with any new
ocular or non-ocular safety ﬁndings.
Pregnancy and lactation: Women of childbearing
potential should use effective contraception during
treatment. No clinical data on exposed pregnancies are
available. Ranibizumab should not be used during
pregnancy unless the expected beneﬁt outweighs the
potential risk to the foetus. For women who wish to
become pregnant and have been treated with ranibizumab,
it is recommended to wait at least 3 months after the last
dose of ranibizumab before conceiving. Breast feeding
is not recommended during the use of Lucentis.
Driving and using machines: The treatment procedure
may induce temporary visual disturbances, and patients
who experience these signs must not drive or use
machines until these disturbances subside.
Undesirable effects: Wet AMD Population: Serious
adverse events related to the injection procedure
included endophthalmitis, rhegmatogenous retinal
detachment, retinal tear, and iatrogenic traumatic
cataract. Other serious ocular events among Lucentis-
treated patients included intraocular inﬂammation and
increased intraocular pressure. The safety data below
includes all adverse events suspected to be due to the
injection procedure or medicinal product in the wet
AMD trial population. Very Common: Intraocular
pressure increased, headache, vitritis, vitreous
detachment, retinal haemorrhage, visual disturbance,
eye pain, vitreous ﬂoaters, conjunctival haemorrhage,
eye irritation, foreign body sensation in eyes, lacrimation
increased, blepharitis, dry eye, ocular hyperaemia, eye
pruritus, arthralgia, nasopharyngitis. Common: Anaemia,
retinal degeneration, retinal disorder, retinal detachment,
retinal tear, detachment of the retinal pigment
epithelium, retinal pigment epithelium tear, visual acuity
reduced, vitreous haemorrhage, vitreous disorder,
uveitis, iritis, iridocyclitis, cataract, cataract subcapsular,
posterior capsule opaciﬁcation, punctuate keratitis,
corneal abrasion, anterior chamber ﬂare, vision blurred,
injection site haemorrhage, eye haemorrhage,
conjunctivitis, conjunctivitis allergic, eye discharge,
photopsia, photophobia, ocular discomfort, eyelid
oedema, eyelid pain, conjunctival hyperaemia, cough,
nausea, allergic reactions, hypersensitivity, and anxiety.
DMO and RVO Populations: Ocular and non-ocular
events in the DMO and RVO trials were reported with a
frequency and severity similar to those seen in the wet
AMD trials with the addition of urinary tract infection,
which was found to be ‘common’ in the DMO
population.
Product-class-related adverse reactions: There is
a theoretical risk of arterial thromboembolic events
following intravitreal use of VEGF inhibitors. A low
incidence rate of arterial thromboembolic events was
observed in the Lucentis clinical trials in patients with
AMD and DMO and RVO, and there were no major
differences between the groups treated with ranibizumab
compared with control.
Please refer to the SmPC for full listing of all
undesirable effects.
For UK: Adverse events should be reported.
Reporting forms and information can be found at
www.yellowcard.gov.uk. Adverse events should also be
reported to Novartis Pharmaceuticals UK Ltd on (01276)
698370.
Legal category: POM, UK Basic NHS cost: d742.17
Marketing authorisation number: EU/1/06/374/001.
Marketing authorisation holder: Novartis Europharm
Limited, Wimblehurst Road, Horsham, West Sussex
RH12 5AB, UK. Full prescribing information,
including SmPC, is available from Novartis
Pharmaceuticals, Frimley Business Park, Frimley,
Camberley, Surrey GU16 7SR. Telephone: 01276 692255;
Fax: 01276 692508.
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